Sona Saira Ramasastry
Direktor/Vorstandsmitglied bei GLENMARK PHARMACEUTICALS LIMITED
Vermögen: 747 930 $ am 30.04.2024
Profil
Sona Saira Ramasastry is the founder of Life Sciences Advisory LLC, which was founded in 2009.
She currently holds several positions as an independent director or member of the board of directors, including at Glenmark Pharmaceuticals Ltd., Vir Biotechnology, Inc., Mirum Pharmaceuticals, Inc., Pain Therapeutics, Inc., Elevian, Inc., DOT Therapeutics-2, Inc., and Day One Biopharmaceuticals, Inc. She is also a member of the Aspen Global Leadership Network and the European Prevention of Alzheimer's Dementia Consortium.
Ms. Ramasastry has held former positions as an independent director at Repros Therapeutics, Inc., Sangamo Therapeutics, Inc., Cassava Sciences, Inc., and 9 Meters Biopharma, Inc. She was also a financial analyst at Wasserstein Perella & Co., Inc. in 1997-1998.
Ms. Ramasastry received her undergraduate and graduate degrees from Stanford University and her graduate degree from the University of Cambridge.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
15.03.2024 | 50 485 ( 0,06% ) | 666 907 $ | 30.04.2024 | |
VIR BIOTECHNOLOGY, INC.
0,01% | 01.06.2023 | 10 619 ( 0,01% ) | 81 023 $ | 30.04.2024 |
15.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Sona Saira Ramasastry
Unternehmen | Position | Beginn |
---|---|---|
GLENMARK PHARMACEUTICALS LIMITED | Direktor/Vorstandsmitglied | 01.04.2019 |
VIR BIOTECHNOLOGY, INC. | Direktor/Vorstandsmitglied | 01.09.2019 |
DAY ONE BIOPHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.03.2021 |
MIRUM PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 02.06.2022 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Direktor/Vorstandsmitglied | 12.04.2021 |
European Prevention of Alzheimer's Dementia Consortium | Corporate Officer/Principal | - |
Elevian, Inc.
Elevian, Inc. Pharmaceuticals: MajorHealth Technology Elevian, Inc. develops medicines that restore youthful regenerative capacity. The company was founded by Mark J. F. Allen, Sebastian Giwa, Peter H. Diamandis, Brock C. Reeve, and Luis Alvarez and is headquartered in Allston, MA. | Direktor/Vorstandsmitglied | - |
Pain Therapeutics, Inc.
Pain Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Pain Therapeutics, Inc. develops drugs. | Direktor/Vorstandsmitglied | - |
Aspen Global Leadership Network | Corporate Officer/Principal | - |
░░░░ ░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ehemalige bekannte Positionen von Sona Saira Ramasastry
Unternehmen | Position | Ende |
---|---|---|
░░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░ ░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Sona Saira Ramasastry
Stanford University | Graduate Degree |
University of Cambridge | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 7 |
---|---|
SANGAMO THERAPEUTICS, INC. | Health Technology |
CASSAVA SCIENCES, INC. | Health Technology |
9 METERS BIOPHARMA, INC. | Health Technology |
GLENMARK PHARMACEUTICALS LIMITED | Health Technology |
VIR BIOTECHNOLOGY, INC. | Health Technology |
DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
MIRUM PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 10 |
---|---|
Life Sciences Advisory LLC | |
American Liver Foundation
American Liver Foundation Miscellaneous Commercial ServicesCommercial Services American Liver Foundation engages in facilitating, advocating and promoting education, support, and research for the prevention, treatment, and cure of liver disease. It educates patients, policymakers and the public and provides grants to early-career researchers to help find a cure for all liver diseases. The company was founded in 1976 and is headquartered in New York, NY. | Commercial Services |
Repros Therapeutics, Inc.
Repros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Repros Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the development of drugs to treat hormonal and reproductive systems disorders. Its products include Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in The Woodlands, TX. | Health Technology |
Wasserstein Perella & Co., Inc. | |
Aspen Global Leadership Network | |
Pain Therapeutics, Inc.
Pain Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Pain Therapeutics, Inc. develops drugs. | Health Technology |
Elevian, Inc.
Elevian, Inc. Pharmaceuticals: MajorHealth Technology Elevian, Inc. develops medicines that restore youthful regenerative capacity. The company was founded by Mark J. F. Allen, Sebastian Giwa, Peter H. Diamandis, Brock C. Reeve, and Luis Alvarez and is headquartered in Allston, MA. | Health Technology |
Akouos, Inc.
Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
European Prevention of Alzheimer's Dementia Consortium | |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Health Technology |